DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands

Alsaeedi, Mona Sunaydih; Babgi, Bandar A.; Abdellattif, Magda H.; Jedidi, Abdesslem; Humphrey, Mark G.; Hussien, Mostafa A.

doi:10.3390/molecules26010076

Cited by 10 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hypochromism values (discounting the dilution effect) resulting from this experiment show that practically only complex C1 interacts with DNA, presenting 25% hypochromism, while C2 and C3 present irrelevant hypochromism values. Complex C1 displays a k b constant value equal to 2.5 × 10 4 ± 0.6 × 10 4 , with a magnitude of 10 4 corresponding from a medium/strong interaction with DNA. − …”

Section: Resultsmentioning

confidence: 99%

“Half-Sandwich” Ruthenium Complexes with Alizarin as Anticancer Agents: In Vitro and In Vivo Studies

et al. 2023

View full text Add to dashboard Cite

Upon exploration of the chemistry of the combination of ruthenium/arene with anthraquinone alizarin (L), three new complexes with the general formulas [Ru(L)Cl(η6-p-cymene)] (C1), [Ru(L)(η6-p-cymene)(PPh3)]PF6 (C2), and [Ru(L)(η6-p-cymene)(PEt3)]PF6 (C3) were synthesized and characterized using spectroscopic techniques (mass, IR, and 1D and 2D NMR), molar conductivity, elemental analysis, and X-ray diffraction. Complex C1 exhibited fluorescence, such as free alizarin, while in C2 and C3, the emission was probably quenched by monophosphines and the crystallographic data showed that hydrophobic interactions are predominant in intermolecular contacts. The cytotoxicity of the complexes was evaluated in the MDA-MB-231 (triple-negative breast cancer), MCF-7 (breast cancer), and A549 (lung) tumor cell lines and MCF-10A (breast) and MRC-5 (lung) nontumor cell lines. Complexes C1 and C2 were more selective to the breast tumor cell lines, and C2 was the most cytotoxic (IC50 = 6.5 μM for MDA-MB-231). In addition, compound C1 performs a covalent interaction with DNA, while C2 and C3 present only weak interactions; however, internalization studies by flow cytometry and confocal microscopy showed that complex C1 does not accumulate in viable MDA-MB-231 cells and is detected in the cytoplasm only after cell permeabilization. Investigations of the mechanism of action of the complexes indicate that C2 promotes cell cycle arrest in the Sub-G1 phase in MDA-MB-231, inhibits its colony formation, and has a possible antimetastatic action, impeding cell migration in the wound-healing experiment (13% of wound healing in 24 h). The in vivo toxicological experiments with zebrafish indicate that C1 and C3 exhibit the most zebrafish embryo developmental toxicity (inhibition of spontaneous movements and heartbeats), while C2, the most promising anticancer drug in the in vitro preclinical tests, revealed the lowest toxicity in in vivo preclinical screening.

show abstract

Section: Resultsmentioning

confidence: 99%

“Half-Sandwich” Ruthenium Complexes with Alizarin as Anticancer Agents: In Vitro and In Vivo Studies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is important to note that the K b values for compounds Ru1 and Ru2, were higher than those of related Ru( ii ) cymene with (poly)cyclic aromatic diamine ligands (0.4–1.0 × 10 4 ). 46 The negative Δ G values for compounds Ru1–Ru4 signify spontaneous interactions with CT-DNA. 47…”

Section: Resultsmentioning

confidence: 99%

Heterocyclic (pyrazine)carboxamide Ru(ii) complexes: structural, experimental and theoretical studies of interactions with biomolecules and cytotoxicity

Tsaulwayo,

Omondi,

Vijayan

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…A number of Ru(II) p-cymene complexes with cyclic/polycyclic aromatic diamine ligands [ 66 ] manifested better cytotoxic effects than cisplatin against the OVCAR-3, M-14 and HOP-62 cancer cell lines (IC 50 = 4.31–6.31 μM). CT-DNA binding improved with the increase in the delocalization of the aromatic fragment of the ligand.…”

Section: Novel Metal Complexes In Cancer Therapymentioning

confidence: 99%

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Todorov

Kostova

2023

Molecules

View full text Add to dashboard Cite

Since the accidental discovery of the anticancer properties of cisplatin more than half a century ago, significant efforts by the broad scientific community have been and are currently being invested into the search for metal complexes with antitumor activity. Coordination compounds of transition metals such as platinum (Pt), ruthenium (Ru) and gold (Au) have proven their effectiveness as diagnostic and/or antiproliferative agents. In recent years, experimental work on the potential applications of elements including lanthanum (La) and the post-transition metal gallium (Ga) in the field of oncology has been gaining traction. The authors of the present review article aim to help the reader “catch up” with some of the latest developments in the vast subject of coordination compounds in oncology. Herewith is offered a review of the published scientific literature on anticancer coordination compounds of Pt, Ru, Au, Ga and La that has been released over the past three years with the hope readers find the following article informative and helpful.

show abstract

DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands

Cited by 10 publications

References 51 publications

“Half-Sandwich” Ruthenium Complexes with Alizarin as Anticancer Agents: In Vitro and In Vivo Studies

“Half-Sandwich” Ruthenium Complexes with Alizarin as Anticancer Agents: In Vitro and In Vivo Studies

Heterocyclic (pyrazine)carboxamide Ru(ii) complexes: structural, experimental and theoretical studies of interactions with biomolecules and cytotoxicity

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Contact Info

Product

Resources

About